<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02221999</url>
  </required_header>
  <id_info>
    <org_study_id>RenJiH-BC-002</org_study_id>
    <nct_id>NCT02221999</nct_id>
  </id_info>
  <brief_title>Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients</brief_title>
  <acronym>SHPD002</acronym>
  <official_title>A Prospective, Randomized, Open-label Comparison of Preoperative Weekly Paclitaxel and Cisplatin With or Without Endocrine Therapy in Patients With Operable Hormone Receptor Positive and Triple Negative Locally Advanced Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>RenJi Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>RenJi Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The investigators hypothesize that paclitaxel combined with cisplatin in a weekly-based
      regimen as neoadjuvant chemotherapy is effective and tolerable for locally advanced breast
      cancer.

      In patients with some sub-type advanced breast cancer, neo-adjuvant chemotherapy combined
      with endocrine therapy may improve the pathological remission rate.

      Premenopausal patients with triple negative breast caner and hormonal receptor positve breast
      cancer patients will be randominzed to have neoadjuvant chemotherapy combined with endocrine
      therapy or not.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this trial, patients with ER and or PR positive breast cancer will be separately
      randomized to have chemotherapy or chemotherapy combined with endocrine therapy according to
      their menstrual status. Letrozole for the postmenopausal women and ovarian function
      suppression for the premenopausal women. Patients with triple negative breast cancer will be
      randomized to have neoadjuvant chemotherapy combined with ovarian function suppression if she
      is premenopausal. Postermenopausal patients with triple negative breast caner will only have
      neoadjuvant chemotherapy.

      Patients with Her2 overexpression can obtain anti-Her2 target therapy. This study has been
      amended to a 1:2 ratio to control and neoadjuvant chemotherapy combination of endocrine
      therapy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2014</start_date>
  <completion_date type="Anticipated">October 2022</completion_date>
  <primary_completion_date type="Anticipated">July 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>pathological complete remission rate</measure>
    <time_frame>after 4 months preoperative treatment</time_frame>
    <description>Pathological complete remission is defined as no invasive cancer in breast and axillary nodes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Drug Related Treatment Adverse Events</measure>
    <time_frame>4 months during neoadjuvant therapy</time_frame>
    <description>Adverse events that occurred on or after initial treatment that were absent before treatment or worsened during the treatment period relative to the pretreatment state.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical and imaging response</measure>
    <time_frame>4 months during treatment</time_frame>
    <description>To determine the response rates of the breast tumor and axillary nodes based on physical examination and imaging tests. (sonography, mammography, or MRI) after treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>regional recurrence free survival (RRFS)</measure>
    <time_frame>5 years</time_frame>
    <description>RRFS is defined as the time period between registration and first event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>local recurrence free survival (LRFS)</measure>
    <time_frame>5 years</time_frame>
    <description>LRFS is defined as the time period between registration and first event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>OS is defined as the time period between registration and first event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>distant-disease- free survival (DDFS)</measure>
    <time_frame>5 years</time_frame>
    <description>DDFS is defined as the time period between registration and first event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>rate of tumor remission （RTR）</measure>
    <time_frame>after 2 cycles and 4 cycles during neoadjuvant therapy</time_frame>
    <description>RTR is defined as the proportion of tumor remission per unit time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>serum markers</measure>
    <time_frame>Pre-treatment and/or surgical</time_frame>
    <description>Changes in the angiogenic serum markers(mirRNA, lncRNA, cirRNA), measured at diagnosis and surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>molecular markers</measure>
    <time_frame>Pre-treatment and/or surgical</time_frame>
    <description>Pre-treatment and surgical expression of molecular markers （LHRHa receptor, EGFR，PD-L1)</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">250</enrollment>
  <condition>Tubular Breast Cancer</condition>
  <condition>Mucinous Breast Cancer</condition>
  <condition>Invasive Ductal Breast Cancer</condition>
  <condition>Inflammatory Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy only</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Paclitaxel injection 80mg/m2,given on days1,8,15 and 22 of a 28-day cycle；Cisplatin 25mg/m2, given on days 1,8,and 15 of a 28-day cycle； for 4 cycles</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GnRHa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 80mg/m2,given on days1,8,15 and 22 of a 28-day cycle; Cisplatin 25mg/m2, given on days 1,8,and 15 of a 28-day cycle; for 4 cycles Gonadotropin-releasing hormone agonist （GnRHa）11.25 mg every 3 months or 3.6mg every month subcutaneously</description>
  </arm_group>
  <arm_group>
    <arm_group_label>letrozole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Paclitaxel 80mg/m2,given on days1,8,15 and 22 of a 28-day cycle; Cisplatin 25mg/m2, given on days 1,8,and 15 of a 28-day cycle; for 4 cycles Letrozole 2.5mg/day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Paclitaxel</intervention_name>
    <arm_group_label>Chemotherapy only</arm_group_label>
    <arm_group_label>GnRHa</arm_group_label>
    <arm_group_label>letrozole</arm_group_label>
    <other_name>Taxol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cisplatin</intervention_name>
    <arm_group_label>Chemotherapy only</arm_group_label>
    <arm_group_label>GnRHa</arm_group_label>
    <arm_group_label>letrozole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gonadotropin-releasing hormone agonist</intervention_name>
    <description>Goserelin 3.6 mg q28d or Leuprolide 11.25 mg q3m</description>
    <arm_group_label>GnRHa</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Letrozole</intervention_name>
    <arm_group_label>letrozole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Women aged ≥18years and ≤70 years;

          2. At least on measurable disease according to the Response Evaluation Criteria in Solid
             Tumors (RECIST). Histologically confirmed invasive breast cancer, tumor size ≥2 cm,
             T2-4 N0-2M0;

          3. ER/PR/HER-2 and Ki-67 status detected on core biopsy. ER and/or PR positive was
             defined as &gt;1% stained cells.HER2-positive is defined as immuno-histochemistry (IHC)
             3+ or the ratio of HER2 gene signals to chromosome 17 signals &gt;2.0 or HER2 gene copy
             &gt;6.0.

          4. No prior systemic or loco-regional treatment of breast cancer;

          5. Adequate bone marrow function:WBC≥4.0×109/L, Absolute neutrophil count（ANC）≥1.5×109/L,
             Platelets（PLT）≥100×109/L, Hemoglobin（Hb）≥90g/L;aspartate aminotransferase(AST),Alanine
             aminotransferase (ALT)≤1.5 upper normal limit (UNL), creatinine≤1.5 UNL,
             bilirubin≤1.5UNL;

          6. No obvious main organs dysfunction.

        Exclusion Criteria:

          1. Unwilling or unable to use an acceptable method of contraception in 8 weeks (including
             8 weeks) after final dose of test drug;

          2. Patient is pregnant or breast feeding;

          3. Inflammatory breast cancer and metastatic breast cancer;

          4. Any evidence of sense or motor nerve disorders;

          5. Patients with medical conditions taht indicate intolerant to neoadjuvant therapy,
             including uncontrolled cardiovascular disease, severe infection;

          6. Any concurrent malignancy other than breast cancer;

          7. Know severe hypersensitivity to any drugs in this study.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Jinsong Lu, MD</last_name>
    <email>lujjss@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>HanDan Central Hospital</name>
      <address>
        <city>Handan</city>
        <state>Hebei</state>
        <zip>056001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yinzhou Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of University of South China</name>
      <address>
        <city>Hengyang</city>
        <state>Hunan</state>
        <zip>421001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongguang Liu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>The second people's hospital of Kunshan city</name>
      <address>
        <city>Kunshan</city>
        <state>Jiangsu</state>
        <zip>215300</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bei Gu, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhongshan Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongwei Zhang, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shanghai Jiaotong University School of Medicine, Renji Hospital</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200127</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jinsong Lu, MD</last_name>
      <email>lujjss@163.com</email>
    </contact>
    <investigator>
      <last_name>Jinsong Lu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yueyang hospital of integrated traditional Chinese and Western medine</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200437</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaohong Xue, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Armed Police Corps Hospital of Shanghai</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>201103</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yumei Ye, MD</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Zhoushan hospital</name>
      <address>
        <city>Zhoushan</city>
        <state>Zhejiang</state>
        <zip>316021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jing Xu, MD</last_name>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 14, 2014</study_first_submitted>
  <study_first_submitted_qc>August 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 21, 2014</study_first_posted>
  <last_update_submitted>December 20, 2017</last_update_submitted>
  <last_update_submitted_qc>December 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">December 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>RenJi Hospital</investigator_affiliation>
    <investigator_full_name>Jinsong Lu</investigator_full_name>
    <investigator_title>Director of Breast Surgery</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Inflammatory Breast Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Ductal, Breast</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Letrozole</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Hormones</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

